Fluticasone Propionate And Salmeterol Powder, Metered
Product Images NDC 0093-3608

Product Visual Gallery

This gallery contains 24 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol (NDC 0093-3608). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fp Chem Structure (Fluticasone Propionate Salmeterol Inhalation Powde 1)

Chemical structure of Fluticasone Propionate, one of the active ingredients in Fluticasone Propionate and Salmeterol inhalation powder by Teva Pharmaceuticals USA, Inc.*

FDA Label Image

Figure 8 (Fluticasone Propionate Salmeterol Inhalation Powde 10)

A line graph depicting the mean change in FEV1 over 12 hours following inhalation of Fluticasone Propionate and Salmeterol (FS MDPI) at doses 232 mcg and 113 mcg, Fluticasone Propionate (FP MDPI) at doses 232 mcg and 113 mcg, and placebo. The x-axis shows time in hours post-dose, and the y-axis demonstrates mean change in FEV1 values, with FS MDPI treatments showing higher improvement compared to FP MDPI and placebo.*

FDA Label Image

Teva Logo (Fluticasone Propionate Salmeterol Inhalation Powde 11)

FDA Label Image

Teva Logo (Fluticasone Propionate Salmeterol Inhalation Powde 12)

FDA Label Image

Figurr A (Fluticasone Propionate Salmeterol Inhalation Powde 13)

Illustration of a Fluticasone Propionate and Salmeterol powder inhaler showing key parts: mouthpiece, vent, yellow cap, and dose counter. The diagram highlights the inhaler components relevant to its operation and use.*

FDA Label Image

Figure B (Fluticasone Propionate Salmeterol Inhalation Powde 14)

An illustration showing the dose counter window of a respiratory inhaler device. The first image shows a full inhaler with 60 doses remaining, displaying the numbers 58 and 60. The second image shows an empty inhaler with 0 doses remaining, highlighted in red.*

FDA Label Image

Figure C (Fluticasone Propionate Salmeterol Inhalation Powde 15)

An instructional illustration showing hands holding an inhaler device and its yellow protective cap, demonstrating the action of removing or attaching the cap to the inhaler with a 'CLICK' sound indicated, related to the use of Fluticasone Propionate and Salmeterol inhalation powder.*

FDA Label Image

Figure D (Fluticasone Propionate Salmeterol Inhalation Powde 16)

Instructional illustration showing how to properly attach a yellow cap or mouthpiece to a respiratory inhaler device, indicating the correct and incorrect methods of attachment using check and cross marks.*

FDA Label Image

Breathe Out Image (Fluticasone Propionate Salmeterol Inhalation Powde 17)

An illustration showing a side profile of a person's face exhaling or releasing a mist or powder from the mouth. This diagram likely represents the use or administration of a respiratory inhalation product such as Fluticasone Propionate and Salmeterol metered powder inhaler.*

FDA Label Image

Figure F (Fluticasone Propionate Salmeterol Inhalation Powde 18)

An instructional illustration showing a person using a metered-dose inhaler. The hand is holding the inhaler with a yellow mouthpiece cover, while the inhaler is positioned near the person's open mouth for inhalation.*

FDA Label Image

Figure G (Fluticasone Propionate Salmeterol Inhalation Powde 19)

An instructional diagram showing a close-up view of a metered dose inhaler with a labeled vent near the mouthpiece. The image highlights the vent location on the respiratory inhalation device for Fluticasone Propionate and Salmeterol powder.*

FDA Label Image

Salmeterol Chem Structure (Fluticasone Propionate Salmeterol Inhalation Powde 2)

Chemical structure diagram of the active ingredient Fluticasone Propionate and Salmeterol, showing the detailed molecular arrangement of atoms and bonds.*

FDA Label Image

Figure H (Fluticasone Propionate Salmeterol Inhalation Powde 20)

An instructional illustration showing hands holding a powder metered inhaler for respiratory use. The image depicts the cap being removed from the inhaler by lifting it upward, indicated by an arrow. This is part of the usage instructions for Fluticasone Propionate and Salmeterol inhalation powder.*

FDA Label Image

Teva Logo (Fluticasone Propionate Salmeterol Inhalation Powde 21)

FDA Label Image

Ndc 0093-3607-82 (Carton)

Packaging label for Fluticasone Propionate and Salmeterol Inhalation Powder, 55 mcg / 14 mcg strength, metered powder for respiratory inhalation. The label shows the product name, strength, dosage form, route, quantity (60 metered inhalations, 0.45 g net contents), and the labeler Teva Pharmaceuticals USA, Inc. Includes dosing counter indication and barcode.*

FDA Label Image

113 Mcg/ 14 Mcg Carton (NDC 0093-3608-82)

Packaging label for Fluticasone Propionate and Salmeterol Inhalation Powder, 113 mcg / 14 mcg, metered powder for oral inhalation. The label shows the product name, strength, dosage form, and includes 'With Dose Counter' in green text. The labeler is Teva Pharmaceuticals USA, Inc. The package contains 60 metered inhalations with net content 0.45 g. It includes NDC 0093-3608-82 and barcode information.*

FDA Label Image

232 Mcg / 14 Mcg Carton (NDC 0093-3609-82)

Packaging label for Fluticasone Propionate and Salmeterol inhalation powder, strength 232 mcg / 14 mcg, metered powder for oral inhalation only. The label indicates the product includes 60 metered inhalations with a net content of 0.45 g and features a dose counter. Manufactured by Teva Pharmaceuticals USA, Inc. The label also includes a barcode and NDC 0093-3609-82.*

FDA Label Image

Figure 1 (Fluticasone Propionate Salmeterol Inhalation Powde 3)

A two-panel graph comparing Trial 201 and Trial 202 results, showing the difference from placebo with 95% confidence intervals for Fluticasone Propionate and Salmeterol dry powder inhaler treatments. The x-axis lists various metered doses in micrograms BID, and the y-axis shows the effect difference from placebo. The figure includes key for Fp MDPI (fluticasone propionate multidose dry powder inhaler) and Fp DPI (fluticasone propionate dry powder inhaler comparator).*

FDA Label Image

Figure 2 (Fluticasone Propionate Salmeterol Inhalation Powde 4)

A line graph showing baseline-adjusted FEV1 (mL) over time (hours) up to 12 hours for various dosages of Fluticasone Propionate and Salmeterol metered dose inhaler (MDPI) and dry powder inhaler (DPI) formulations. The graph compares multiple dosage strengths and product forms, illustrating changes in lung function across the time course.*

FDA Label Image

Figure 3 (Fluticasone Propionate Salmeterol Inhalation Powde 5)

A line graph showing mean change in FEV1 (L) over 12 weeks for different dosages of Fluticasone Propionate and Salmeterol metered powder inhalation (MDPI) and placebo. The graph includes data for FS MDPI doses of 113 mcg/14 mcg and 55 mcg/14 mcg, FP MDPI doses of 113 mcg and 55 mcg, and placebo, with sample sizes indicated below the x-axis at multiple time points (weeks 0 to 12).*

FDA Label Image

Figure 4 (Fluticasone Propionate Salmeterol Inhalation Powde 6)

A line graph depicting the mean change in FEV1 (L) over 12 hours from baseline (Day 1) in patients receiving Fluticasone Propionate and Salmeterol and comparators. It compares FS MDPI 113 mcg/14 mcg, FS MDPI 55 mcg/14 mcg, FP MDPI 113 mcg, FP MDPI 55 mcg, and placebo groups. The graph shows respiratory drug effects over time post-dose.*

FDA Label Image

Figure 5 (Fluticasone Propionate Salmeterol Inhalation Powde 7)

A line graph displaying the mean change in FEV1 (L) over a 12-hour period for different groups: FS MDPI 113 mcg/14 mcg, FS MDPI 55 mcg/14 mcg, FP MDPI 113 mcg, FP MDPI 55 mcg, and a placebo group. The x-axis represents time in hours, and the y-axis shows the mean change in FEV1, with data points illustrating changes from baseline measured at Day 1 and Week 12.*

FDA Label Image

Figure 6 (Fluticasone Propionate Salmeterol Inhalation Powde 8)

A line graph showing the mean change in FEV1 (liters) over 12 weeks for different doses of Fluticasone Propionate and Salmeterol metered dose inhaler (MDPI) formulations (232 mcg/14 mcg and 113 mcg/14 mcg) compared with placebo. The x-axis represents weeks of treatment, and the y-axis represents mean change in FEV1 with values ranging from -0.1 to 0.5 liters. Data points for each group are presented with different markers, indicating the progression of lung function over time.*

FDA Label Image

Figure 7 (Fluticasone Propionate Salmeterol Inhalation Powde 9)

A line graph depicting the mean change in FEV1 (liters) over 12 hours following administration of different doses of Fluticasone Propionate and Salmeterol (FS MDPI) and Fluticasone Propionate alone (FP MDPI), compared to placebo. The graph shows multiple curves for FS MDPI 232 mcg/14 mcg, FS MDPI 113 mcg/14 mcg, FP MDPI 232 mcg, FP MDPI 113 mcg, and placebo, with FEV1 change peaking within the first few hours after baseline (Day 1).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.